[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
2005, Volume 35, Number 3, Page(s) 132-135
[ Summary ] [ Full Text ] [ PDF ]
5-Fluorouracil, epirubicin and cisplatin (FEP) in the treatment of metastatic gastric carcinoma
ÖZKAN KANAT1, TÜRKKAN EVRENSEL1, ENDER KURT1, MUTLU DEMİRAY1, MURAT ARSLAN1, GÜZİN GÖNÜLLÜ1, NALAN BABACAN2, ABDÜLMECİT YILDIZ2, OSMAN MANAVOĞLU1
1Uludağ University Medical Faculty, Departments of Medical Oncology, Bursa-Turkey
2Uludağ University Medical Faculty, Departments of Internal Medicine, Bursa-Turkey

In this retrospective study, we evaluated the activity and toxicity of the combination of 5-fluorouracil (5-FU), epirubicin and cisplatin (FEP) in previously untreated patients with metastatic gastric cancer. Sixty-five patients received 5-FU 300 mg/m2 on days 1-5, epirubicin 50 mg/m2 on day 1 and cisplatin 60 mg/m2 on day 1, every 4 weeks. A median of 4 cycles was administered. There were 4 partial responses and 1 complete response (overall response rate 7.6%); 16 patients had stable disease. Median progression-free and overall survival rates were 3 months (95% CI 1.9-4) and 6 months (95% CI 4.2-7), respectively. The principal toxicity was myelosuppression. Grade 3-4 neutropenia occurred in 29.2%, anemia in 18.4%, and thrombocytopenia in 12.3% of patients. Non-hematological toxicity was mild and manageable. We concluded that FEP combination as used at the doses and schedules in this study has inferior activity against metastatic gastric cancer. [Turk J Cancer 2005;35(3):132-135].

[ Summary ] [ Full Text ] [ PDF ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]